BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Mabwell Therapeutics\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Mabwell Therapeutics\, Inc.'s dru
 gs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06985147-10341@assetmemo.bio
DTSTAMP:20261121T010211Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:DISC-3405: Phase 2 readout est. (NCT06985147)
DESCRIPTION:DISC-3405\, phase 2\, Polycythemia Vera.\nStudy: A Phase 2\, Op
 en-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)\nE
 stimated primary completion: July 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/disc-3405#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06985147
URL:https://assetmemo.bio/drug/disc-3405#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
